Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions

References

• DhillonS. Regorafenib: a review in metastatic colorectal cancer. Drugs. 2018;78(11):1133–1144. doi:10.1007/s40265-018-0938-y29943375
   PubMed Web of Science ®Google Scholar
• ShirleyM, KeatingGM. Regorafenib: a review of its use in patients with advanced gastrointestinal stromal tumours. Drugs. 2015;75(9):1009–1017. doi:10.1007/s40265-015-0406-x25998375
   PubMed Web of Science ®Google Scholar
• HeoYA, SyedYY. Regorafenib: a review in hepatocellular carcinoma. Drugs. 2018;78(9):951–958. doi:10.1007/s40265-018-0932-429915898
   PubMed Web of Science ®Google Scholar
• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• GrotheyA, BlayJY, PavlakisN, YoshinoT, BruixJ. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. doi:10.1016/j.ctrv.2020.10199332199197
   PubMed Web of Science ®Google Scholar
• ParsadS, RatainMJ. Food effect studies for oncology drug products. Clin Pharmacol Ther. 2017;101(5):606–612. doi:10.1002/cpt.61028073144
   PubMed Web of Science ®Google Scholar
• Stivarga® (regorafenib) [prescribing information]. FDA; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf. Accessed July 01, 2021.
   Google Scholar
• Stivarga: summary of product characteristics. Stivarga, Bayer Healthcare; 2015. Available from: https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_en.pdf. Accessed July 01, 2021.
   Google Scholar
• GerischM, HafnerFT, LangD, et al. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol. 2018;81(1):195–206. doi:10.1007/s00280-017-3480-929188322
   PubMed Web of Science ®Google Scholar
• TlemsaniC, HuillardO, ArrondeauJ, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol. 2015;11(5):785–794. doi:10.1517/17425255.2015.103039225809423
   PubMed Web of Science ®Google Scholar
• ZopfD, FichtnerI, BhargavaA, et al. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 2016;5(11):3176–3185. doi:10.1002/cam4.88327734608
   PubMed Web of Science ®Google Scholar
• KeuneckeA, HoefmanS, DrenthHJ, ZisowskyJ, CletonA, PloegerBA. Population pharmacokinetics of regorafenib in solid tumours: exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol. 2020;86(12):2362–2376. doi:10.1111/bcp.1433432358822
   PubMed Web of Science ®Google Scholar
• SunakawaY, FuruseJ, OkusakaT, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014;32(1):104–112. doi:10.1007/s10637-013-9953-823553067
   PubMed Web of Science ®Google Scholar
• FarhaM, MassonE, TomkinsonH, MugunduG. Food effect study design with oral drugs: lessons learned from recently approved drugs in oncology. J Clin Pharmacol. 2019;59(4):463–471.30536979
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products – general considerations; 2002. Available from: https://www.fda.gov/files/drugs/published/Guidance-for-Industry-Bioavailability-and-Bioequivalence-Studies-for-Orally-Administered-Drug-Products—General-Considerations.PDF. Accessed 701, 2021.
   Google Scholar
• FDA. Draft guidance on regorafenib; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203085.pdf. Accessed 701, 2021.
   Google Scholar
• StrumbergD, ScheulenME, SchultheisB, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722–1727. doi:10.1038/bjc.2012.15322568966
   PubMed Web of Science ®Google Scholar
• FDA. Draft guidance on regorafenib; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Regorafenib_tab_203085_RC12-14.pdf. Accessed 701, 2021.
   Google Scholar
• FDA. Clinical pharmacology and biopharmaceutics review(S) [Stivarga]; 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000ClinPharmR.pdf. Accessed 701, 2021.
   Google Scholar
• MedDRA MS. Introductory guide for standardised MedDRA queries (SMQs) Version 23.1. Available from: https://admin.new.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_1_English.pdf. Accessed 701, 2021.
   Google Scholar
• DueckAC, MendozaTR, MitchellSA, et al. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–1059. doi:10.1001/jamaoncol.2015.263926270597
   PubMed Web of Science ®Google Scholar
• MrossK, FrostA, SteinbildS, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–2667. doi:10.1158/1078-0432.CCR-11-190022421192
   PubMed Web of Science ®Google Scholar
• LiJ, QinS, XuR, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2015;16(6):619–629. doi:10.1016/S1470-2045(15)70156-725981818
   PubMed Web of Science ®Google Scholar
• SonbolMB, BenkhadraR, WangZ, et al. A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer. Oncologist. 2019;24(9):1174–1179. doi:10.1634/theoncologist.2019-018931164455
   PubMed Web of Science ®Google Scholar
• GuanX, LiH, XiongX, et al. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ. 2021;24(1):339–344. doi:10.1080/13696998.2021.188874333571036
   PubMed Web of Science ®Google Scholar
• STIVARGA® product monograph. Bayer, Inc; 2013. Available from: https://omr.bayer.ca/omr/online/stivarga-pm-en.pdf. Accessed 506, 2021.
   Google Scholar